US FDA revokes approval of Avastin for breast cancer treatment

In a surprise move, the US Food and Drug Administration (FDA) has revoked its approval of Avastin for the treatment of breast cancer. Avastin will, however, remain on the market for a number of other conditions, including various types of colon, lung, kidney and brain cancer.

The FDA’s announcement states that after careful consideration, they felt that Avastin could not be proved to help with breast cancer treatment, and that this had been weighed against the potential side effects from the drug. Avastin had been approved for breast cancer treatment back in early 2008.

The FDA has, however, explicitly encouraged Avastin’s sponsor Genentech to consider other tests to determine whether there might be a way forward for Avastin as an effective treatment for breast cancer. So the revokation of approval might turn out to be only temporary.

About Sarah Bosdiccia

Sarah Bosdiccia is a writer, journalist, blogger and editorial assistant. In the past, she has worked in the local newspaper business and has taught journalism modules at undergraduate level. She doesn't 'do' Facebook but you can follow her at @sarah_bosdiccia.


No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

For the latest news

Follow 100gf on Twitter

Subscribe to 100gf | Politics and Computers. Warning: Usually more than 30 posts per day!

%d bloggers like this: